Lee Chan Henry 4
4 · BeOne Medicines Ltd. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
BeOne Medicines (ONC) SVP Lee Chan Henry Exercises Options, Sells Shares
What Happened
- Lee Chan Henry, Senior Vice President and General Counsel of BeOne Medicines (ONC), executed a set of option/derivative transactions and completed open-market sales on Feb 4, 2026. He exercised 1,660 shares via option/derivative exercises (three exercises) by paying roughly $317,721 in aggregate exercise cost, and sold the same number of shares (1,660) in two open-market transactions for total cash proceeds of about $580,197.
- The Form 4 also reports conversion/disposition of additional derivative securities (three entries) totaling 21,580 shares shown with $0 proceeds (these entries reflect conversions/exercises of derivative securities, per the filing). The sale transactions were effected pursuant to a Rule 10b5-1 trading plan.
Key Details
- Transaction date: February 4, 2026; Form 4 filed Feb 6, 2026 (timely filing).
- Option exercises (acquired): 502 shares @ $194.47 = $97,624; 662 shares @ $213.32 = $141,218; 496 shares @ $159.03 = $78,879. Total exercise cost ≈ $317,721.
- Open-market sales (disposed): 664 shares @ $348.79 = $231,597; 996 shares @ $350.00 = $348,600. Total proceeds ≈ $580,197.
- Derivative conversions/dispositions (reported as $0 proceeds): 6,526; 8,606; and 6,448 shares (total 21,580) — listed as exercise/conversion of derivative securities.
- Notable footnotes: F2 — sales were made under a Rule 10b5-1 trading plan adopted May 14, 2025. F1 — each American Depositary Share (if applicable) represents 13 ordinary shares. F3–F6 — vesting schedules and that option/exercise figures are represented in ordinary shares.
- Shares owned after the transactions: not specified in the excerpt of the filing.
Context
- The filing shows option/derivative exercises (Form 4 code M) and contemporaneous open-market sales (Form 4 code S). Exercising options and then selling shares the same day is common (e.g., to cover exercise costs or taxes), but the filing does not state the insider’s motive.
- The sales were performed under a pre-arranged 10b5-1 plan, which indicates the trades were executed according to a previously adopted plan rather than ad hoc decisions.
- Derivative entries at $0 are conversions/exercises of derivative securities (e.g., option/RSU settlements); these are procedural steps and do not necessarily imply additional cash proceeds.
Insider Transaction Report
Form 4
Lee Chan Henry
SVP, General Counsel
Transactions
- Exercise/Conversion
American Depositary Shares
[F1]2026-02-04$194.47/sh+502$97,624→ 502 total - Exercise/Conversion
American Depositary Shares
[F1]2026-02-04$213.32/sh+662$141,218→ 1,164 total - Exercise/Conversion
American Depositary Shares
[F1]2026-02-04$159.03/sh+496$78,879→ 1,660 total - Sale
American Depositary Shares
[F1][F2]2026-02-04$348.79/sh−664$231,597→ 996 total - Sale
American Depositary Shares
[F1][F2]2026-02-04$350.00/sh−996$348,600→ 0 total - Exercise/Conversion
Share Option (Right to Buy)
[F3][F4]2026-02-04−6,526→ 23,920 totalExercise: $14.96Exp: 2032-08-04→ Ordinary Shares (6,526 underlying) - Exercise/Conversion
Share Option (Right to Buy)
[F3][F5]2026-02-04−8,606→ 88,413 totalExercise: $16.41Exp: 2033-06-14→ Ordinary Shares (8,606 underlying) - Exercise/Conversion
Share Option (Right to Buy)
[F3][F6]2026-02-04−6,448→ 111,670 totalExercise: $12.23Exp: 2034-06-04→ Ordinary Shares (6,448 underlying)
Holdings
- 223,106
Ordinary Shares
Footnotes (6)
- [F1]Each American Depositary Share represents 13 Ordinary Shares.
- [F2]The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.
- [F3]The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
- [F4]These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
- [F5]These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
- [F6]These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
Signature
/s/ Qing Nian, as Attorney-in-Fact|2026-02-06